The Company has Assembled an All-Star Team
8
Executive Management
Jay Kranzler, MD PhD
Chairman, Chief Executive Officer & Director
• Founding Member, McKinsey Pharmaceutical Practice
• 24 years as CEO of 2 public companies (with 2 rheumatology product approvals), followed by senior executive position at Pfizer
• Professor at NYU Medical & Business Schools
• Founder, Board Member, and Advisor to an extensive number of companies and institutions
Raymond Zheng, PhD MBA
Founder and Chief Scientific Officer
• Experienced Biotech Entrepreneur with combined 20+ years of experience in drug research, discovery and development
• Previously held multiple business development roles at Fortress Biotech, Agenus, and Harvard Medical School
• PhD from University of California, Riverside; Fellowship at Harvard Medical School; MBA from Rutgers University
Scott Baumgartner, MD
Interim Chief Medical Officer
• Previously VP of Medical Affairs at AstraZeneca/Ardea Biosciences and Amgen
• Experienced in the clinical development and post-launch activities of Lesinurad and Verinurad
• MD from University of Washington with 20 years of clinical rheumatology experience
Board of Directors
Paul Brooke
Co - Chairman
• Chairman Emeritus of the Board of Caelum Biosciences, acquired by AstraZeneca in Oct 2021
• Founder and former Managing Partner of venBio, a pharmaceutical investment company
• Former global head of healthcare research and strategy at Morgan Stanley
Lindsay Rosenwald, MD
Founder & Director
• Chairman, President, and CEO at Fortress Biotech (NASDAQ: FBIO)
• Previously, Founder of multiple biotech companies: Cougar Biotechnology (acquired by JNJ), Caelum Biosciences (acquired by Astra
Zeneca), Chelsea Therapeutics (acquired by Lundbeck), Indevus Pharma (acquired by Endo), Biocryst, Keryx, CorMedix, and Ziopharm
Vibeke Strand, MD
Director
• Renowned rheumatologist and Consultant and Advisor for three decades to companies, FDA, and professional societies in the field
• Participated in 30+ rheumatology drug approvals
• Academic appointments at UCSF and Stanford, each for 10+ years with ~500 publications in the field
Scientific Advisory Board
Robert Terkeltaub, MD
Univ. of California, San Diego, Chief of Rheumatology
• Professor of Medicine, UCSD, and Section Chief of Rheumatology at the VA Medical Center in San Diego
• Associate Editor of Arthritis and Rheumatism, and serves on numerous NIH Study Sections in arthritis
• Graduate of McGill University, where completed his medicine residency and rheumatology fellowship
Dr. Michael Pillinger, MD
New York Univ., Chief of Rheumatology
• Chief of Rheumatology at VA NY Harbor Healthcare System, Professor of Medicine at NYC Grossman School of Medicine
• Received medical degree from NYU School of Medicine; has practiced rheumatology for more than 20 years
Dr. Lee Simon, MD
Medical and Regulatory Consultant
• FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products (2001-2003)
• Long-time NIH-funded investigator, two-term ACR Board of Directors, Chair of Education for the ACR and National Arthritis Foundation